105 related articles for article (PubMed ID: 11768029)
21. Relationship of a new histological categorization of ductal carcinoma in situ of the breast with size and the immunohistochemical expression of p53, c-erb B2, bcl-2, and ki-67.
Mack L; Kerkvliet N; Doig G; O'Malley FP
Hum Pathol; 1997 Aug; 28(8):974-9. PubMed ID: 9269835
[TBL] [Abstract][Full Text] [Related]
22. C-erb-B2 gene amplification and serum level of c-erb-B2 oncoprotein at primary breast cancer diagnosis.
Fontana X; Ferrari P; Namer M; Peysson R; Salanon C; Bussiere F
Anticancer Res; 1994; 14(5B):2099-104. PubMed ID: 7840506
[TBL] [Abstract][Full Text] [Related]
23. Cluster analysis of p-glycoprotein, c-erb-B2 and P53 in relation to tumor histology strongly indicates prognosis in patients with operable non-small cell lung cancer.
Bozcuk H; Gumus A; Ozbilim G; Sarper A; Kucukosmanoglu I; Ozbudak IH; Artac M; Ozdogan M; Samur M; Kaya A; Savas B
Med Sci Monit; 2005 Jun; 11(6):HY11-20. PubMed ID: 15917726
[TBL] [Abstract][Full Text] [Related]
24. Apoptosis and cell proliferation: correlation with BCL-2 and P53 oncoprotein expression in human hepatocellular carcinoma.
EI-Emshaty HM; Saad EA; Toson EA; Abdel Malak CA; Gadelhak NA
Hepatogastroenterology; 2014; 61(133):1393-401. PubMed ID: 25436317
[TBL] [Abstract][Full Text] [Related]
25. c-erbB-2 oncoprotein is overexpressed in poorly vascularised squamous cell carcinomas of the head and neck, but is not associated with response to cytotoxic therapy or survival.
Giatromanolaki A; Koukourakis MI; Sivridis E; Fountzilas G
Anticancer Res; 2000; 20(2A):997-1004. PubMed ID: 10810387
[TBL] [Abstract][Full Text] [Related]
26. Co-expression of p53 and bcl-2 may correlate to the presence of epstein-barr virus genome and the expression of proliferating cell nuclear antigen in nasopharyngeal carcinoma.
Niemhom S; Kitazawa S; Murao S; Kunachak S; Maeda S
Cancer Lett; 2000 Nov; 160(2):199-208. PubMed ID: 11053650
[TBL] [Abstract][Full Text] [Related]
27. Expression of the c-erb-B2 and p53 protein in gallbladder carcinomas.
Kim YW; Huh SH; Park YK; Yoon TY; Lee SM; Hong SH
Oncol Rep; 2001; 8(5):1127-32. PubMed ID: 11496329
[TBL] [Abstract][Full Text] [Related]
28. The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer.
Korkolopoulou P; Christodoulou P; Kapralos P; Exarchakos M; Bisbiroula A; Hadjiyannakis M; Georgountzos C; Thomas-Tsagli E
Pathol Res Pract; 1997; 193(11-12):767-75. PubMed ID: 9521509
[TBL] [Abstract][Full Text] [Related]
29. [Mucoepidermoid carcinoma of salivary glands: the prognostic value of tumoral markers].
Hoyek-Gebeily J; Nehmé E; Aftimos G; Sader-Ghorra C; Sargi Z; Haddad A
Rev Stomatol Chir Maxillofac; 2007 Dec; 108(6):482-8. PubMed ID: 17761202
[TBL] [Abstract][Full Text] [Related]
30. TGF-beta1 and C-erb-B2 neu oncoprotein in Egyptian HCV related chronic liver disease and hepatocellular carcinoma patients.
El Bassuoni MA; Talaat RM; Ibrahim AA; Shaker OT
Egypt J Immunol; 2008; 15(1):39-50. PubMed ID: 20306668
[TBL] [Abstract][Full Text] [Related]
31. Invasion of the bladder by transitional cell carcinoma: its relation to histologic grade and expression of p53, MIB-1, c-erb B-2, epidermal growth factor receptor, and bcl-2.
Vollmer RT; Humphrey PA; Swanson PE; Wick MR; Hudson ML
Cancer; 1998 Feb; 82(4):715-23. PubMed ID: 9477105
[TBL] [Abstract][Full Text] [Related]
32. Epidermoid carcinoma of the lip: an immunohistochemical study.
García-Montesinos-Perea B; Val-Bernal JF; Saiz-Bustillo R
Med Oral Patol Oral Cir Bucal; 2005; 10(5):454-61. PubMed ID: 16264381
[TBL] [Abstract][Full Text] [Related]
33. Expression of proliferating cell nuclear antigen (PCNA) and p53, bcl-2 or C-erb B-2 proteins on Reed-Sternberg cells: prognostic significance in Hodgkin's disease.
Smolewski P; Niewiadomska H; Błonski JZ; Robak T; Krykowski E
Neoplasma; 1998; 45(3):140-7. PubMed ID: 9717525
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of P-glycoprotein, HER-2/ErbB-2, p53, and Bcl-2 in primary tumor and metachronous lung metastases in patients with high-grade osteosarcoma.
Ferrari S; Bertoni F; Zanella L; Setola E; Bacchini P; Alberghini M; Versari M; Bacci G
Cancer; 2004 May; 100(9):1936-42. PubMed ID: 15112275
[TBL] [Abstract][Full Text] [Related]
35. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
36. The p53 positive Bcl-2 negative phenotype is an independent marker of prognosis in breast cancer.
Rolland P; Spendlove I; Madjd Z; Rakha EA; Patel P; Ellis IO; Durrant L
Int J Cancer; 2007 Mar; 120(6):1311-7. PubMed ID: 17187363
[TBL] [Abstract][Full Text] [Related]
37. P-glycoprotein, HER-2/neu, and mutant p53 expression in human gynecologic tumors.
Schneider J; Rubio MP; Barbazán MJ; Rodriguez-Escudero FJ; Seizinger BR; Castresana JS
J Natl Cancer Inst; 1994 Jun; 86(11):850-5. PubMed ID: 7910219
[TBL] [Abstract][Full Text] [Related]
38. Muscle invasive schistosomal squamous cell carcinoma of the urinary bladder: frequency and prognostic significance of p53, BCL-2, HER2/neu, and proliferation (MIB-1).
Badr KM; Nolen JD; Derose PB; Cohen C
Hum Pathol; 2004 Feb; 35(2):184-9. PubMed ID: 14991535
[TBL] [Abstract][Full Text] [Related]
39. Expression of bcl-2, c-erbB-2, p53, and p21 (waf1-cip1) protein in thyroid carcinomas.
Soda G; Antonaci A; Bosco D; Nardoni S; Melis M
J Exp Clin Cancer Res; 1999 Sep; 18(3):363-7. PubMed ID: 10606183
[TBL] [Abstract][Full Text] [Related]
40. Immunohistochemical expression of Bcl-2 protein in breast lesions: correlation with Bax, p53, Rb, C-erbB-2, EGFR and proliferation indices.
Ioachim EE; Malamou-Mitsi V; Kamina SA; Goussia AC; Agnantis NJ
Anticancer Res; 2000; 20(6B):4221-5. PubMed ID: 11205251
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]